Travere Therapeutics Stock Forward View
| TVTX Stock | USD 31.99 0.90 2.89% |
Travere Stock outlook is based on your current time horizon.
At this time, the RSI of Travere Therapeutics' share price is approaching 47. This usually implies that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Travere Therapeutics, making its price go up or down. Momentum 47
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter 0.0113 | EPS Estimate Current Year 0.9114 | EPS Estimate Next Year 1.8971 | Wall Street Target Price 42.0714 | EPS Estimate Current Quarter (0.09) |
Using Travere Therapeutics hype-based prediction, you can estimate the value of Travere Therapeutics from the perspective of Travere Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Travere Therapeutics using Travere Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Travere using crowd psychology based on the activity and movement of Travere Therapeutics' stock price.
Travere Therapeutics Short Interest
An investor who is long Travere Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Travere Therapeutics and may potentially protect profits, hedge Travere Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 23.8961 | Short Percent 0.1729 | Short Ratio 4.89 | Shares Short Prior Month 14.3 M | 50 Day MA 34.2618 |
Travere Relative Strength Index
The Naive Prediction forecasted value of Travere Therapeutics on the next trading day is expected to be 35.93 with a mean absolute deviation of 1.30 and the sum of the absolute errors of 79.07.Travere Therapeutics Hype to Price Pattern
Investor biases related to Travere Therapeutics' public news can be used to forecast risks associated with an investment in Travere. The trend in average sentiment can be used to explain how an investor holding Travere can time the market purely based on public headlines and social activities around Travere Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Travere Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Travere Therapeutics.
Travere Therapeutics Implied Volatility | 1.45 |
Travere Therapeutics' implied volatility exposes the market's sentiment of Travere Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Travere Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Travere Therapeutics stock will not fluctuate a lot when Travere Therapeutics' options are near their expiration.
The Naive Prediction forecasted value of Travere Therapeutics on the next trading day is expected to be 35.93 with a mean absolute deviation of 1.30 and the sum of the absolute errors of 79.07. Travere Therapeutics after-hype prediction price | USD 32.29 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Travere Therapeutics to cross-verify your projections. Prediction based on Rule 16 of the current Travere contract
Based on the Rule 16, the options market is currently suggesting that Travere Therapeutics will have an average daily up or down price movement of about 0.0906% per day over the life of the 2026-04-17 option contract. With Travere Therapeutics trading at USD 31.99, that is roughly USD 0.029 . If you think that the market is fully incorporating Travere Therapeutics' daily price movement you should consider acquiring Travere Therapeutics options at the current volatility level of 1.45%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-04-17 Travere Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Travere Therapeutics' spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Travere Therapeutics' options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Travere Therapeutics stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Travere Therapeutics' open interest, investors have to compare it to Travere Therapeutics' spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Travere Therapeutics is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Travere. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Travere Therapeutics Additional Predictive Modules
Most predictive techniques to examine Travere price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Travere using various technical indicators. When you analyze Travere charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the Travere Therapeutics' financial statements to predict how it will affect future prices.
Cash | First Reported 2010-09-30 | Previous Quarter 75.2 M | Current Value 110.9 M | Quarterly Volatility 64.2 M |
Travere Therapeutics Naive Prediction Price Forecast For the 2nd of February
Given 90 days horizon, the Naive Prediction forecasted value of Travere Therapeutics on the next trading day is expected to be 35.93 with a mean absolute deviation of 1.30, mean absolute percentage error of 2.36, and the sum of the absolute errors of 79.07.Please note that although there have been many attempts to predict Travere Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Travere Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Travere Therapeutics Stock Forecast Pattern
| Backtest Travere Therapeutics | Travere Therapeutics Price Prediction | Buy or Sell Advice |
Travere Therapeutics Forecasted Value
In the context of forecasting Travere Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Travere Therapeutics' downside and upside margins for the forecasting period are 32.15 and 39.71, respectively. We have considered Travere Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Travere Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Travere Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 118.9686 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 1.2963 |
| MAPE | Mean absolute percentage error | 0.0385 |
| SAE | Sum of the absolute errors | 79.0741 |
Predictive Modules for Travere Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Travere Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Travere Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Travere Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Travere Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Travere Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Travere Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Travere Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Travere Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Travere Therapeutics' historical news coverage. Travere Therapeutics' after-hype downside and upside margins for the prediction period are 28.51 and 36.07, respectively. We have considered Travere Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Travere Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Travere Therapeutics is based on 3 months time horizon.
Travere Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Travere Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Travere Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Travere Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.05 | 3.78 | 0.30 | 0.01 | 8 Events / Month | 7 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
31.99 | 32.29 | 0.94 |
|
Travere Therapeutics Hype Timeline
Travere Therapeutics is at this time traded for 31.99. The entity has historical hype elasticity of 0.3, and average elasticity to hype of competition of -0.01. Travere is anticipated to increase in value after the next headline, with the price projected to jump to 32.29 or above. The average volatility of media hype impact on the company the price is about 61.97%. The price jump on the next news is projected to be 0.94%, whereas the daily expected return is at this time at -0.05%. The volatility of related hype on Travere Therapeutics is about 1791.47%, with the expected price after the next announcement by competition of 31.98. The company reported the previous year's revenue of 233.18 M. Net Loss for the year was (320.63 M) with profit before overhead, payroll, taxes, and interest of 215.28 M. Given the investment horizon of 90 days the next anticipated press release will be in about 8 days. Check out Historical Fundamental Analysis of Travere Therapeutics to cross-verify your projections.Travere Therapeutics Related Hype Analysis
Having access to credible news sources related to Travere Therapeutics' direct competition is more important than ever and may enhance your ability to predict Travere Therapeutics' future price movements. Getting to know how Travere Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Travere Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CGON | CG Oncology Common | (0.83) | 8 per month | 2.58 | 0.08 | 5.15 | (4.40) | 33.66 | |
| TARS | Tarsus Pharmaceuticals | 1.08 | 7 per month | 2.06 | (0.01) | 3.78 | (3.76) | 12.48 | |
| CELC | Celcuity LLC | (3.39) | 8 per month | 2.02 | 0.22 | 7.55 | (2.93) | 17.89 | |
| XENE | Xenon Pharmaceuticals | (1.14) | 10 per month | 1.93 | 0.01 | 3.78 | (2.71) | 10.56 | |
| CNTA | Centessa Pharmaceuticals PLC | (0.03) | 9 per month | 2.67 | 0.01 | 4.97 | (4.08) | 26.54 | |
| AAPG | Ascentage Pharma Group | (2.39) | 9 per month | 0.00 | (0.16) | 5.25 | (6.36) | 16.72 | |
| RARE | Ultragenyx | (1.09) | 10 per month | 0.00 | (0.04) | 7.73 | (4.09) | 51.23 | |
| LEGN | Legend Biotech Corp | 0.67 | 10 per month | 0.00 | (0.27) | 3.83 | (6.84) | 19.65 | |
| APGE | Apogee Therapeutics Common | 1.96 | 8 per month | 2.68 | 0.08 | 4.52 | (3.96) | 23.21 | |
| IRON | Disc Medicine | 3.05 | 10 per month | 0.00 | (0.08) | 4.33 | (4.35) | 14.87 |
Other Forecasting Options for Travere Therapeutics
For every potential investor in Travere, whether a beginner or expert, Travere Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Travere Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Travere. Basic forecasting techniques help filter out the noise by identifying Travere Therapeutics' price trends.Travere Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Travere Therapeutics stock to make a market-neutral strategy. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Travere Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Travere Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Travere Therapeutics shares will generate the highest return on investment. By undertsting and applying Travere Therapeutics stock market strength indicators, traders can identify Travere Therapeutics entry and exit signals to maximize returns.
Travere Therapeutics Risk Indicators
The analysis of Travere Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Travere Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting travere stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.78 | |||
| Semi Deviation | 3.44 | |||
| Standard Deviation | 4.36 | |||
| Variance | 19.02 | |||
| Downside Variance | 13.67 | |||
| Semi Variance | 11.85 | |||
| Expected Short fall | (3.14) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Travere Therapeutics
The number of cover stories for Travere Therapeutics depends on current market conditions and Travere Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Travere Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Travere Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Travere Therapeutics Short Properties
Travere Therapeutics' future price predictability will typically decrease when Travere Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Travere Therapeutics often depends not only on the future outlook of the potential Travere Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Travere Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 78.9 M | |
| Cash And Short Term Investments | 370.7 M |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.